ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)		0 Months Ended
	Sep. 30, 2013 Country	Oct. 23, 2013 Subsequent Event [Member] Patient Stage	Oct. 07, 2013 Subsequent Event [Member] Joint Event	Oct. 23, 2013 Minimum [Member] Subsequent Event [Member]	Oct. 23, 2013 Maximum [Member] Subsequent Event [Member]	Sep. 30, 2013 Central Eastern Europe Countries [Member] Country	Sep. 30, 2013 Middle Eastern & North African Countries [Member] Country	Sep. 30, 2013 Eurasian and African countries [Member] Country
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of countries in which marketing rights of XIAFLEX held								71
Number of women patients expected to enroll in Double-blind multiple-dose study		144
Age of women patients expected to enroll in Double-blind multiple-dose study				18 years	45 years
Number of stages for Phase2a study		2
Period for long-term evaluation of success study			5 years
Percentage of patients previously successfully treated not experienced disease recurrence (in hundredths)			57.90%
Number of joints assessed			623
Percentage of joints received medical surgical intervention through year four (in hundredths)			12.80%
Number of serious AEs reported			86
Period of follow up for serious AEs reported			4 years
Number of serious AEs reported related to XIAFLEX			1
Number of countries under the collaboration agreement	28					18	22